BSE: BIOCON - Biocon Limited

半年間の収益性: +5.38%

プロモーションスケジュール Biocon Limited

詳細なスケジュール 簡易グラフ
Financial Markets by TradingView

会社について

Biocon Limited, together with its subsidiaries, engages in the manufacture and sale of biotechnology products and research services in India, Brazil, Singapore, and internationally. It operates through four segments: Generics, Novel Biologics, Biosimilars, and Research Services.

さらに詳しく
The company offers generic formulations and API products, including anti-diabetics, immunosuppressants, multiple sclerosis, anti-cancer/oncology, and other products; novel biologics products, such as head and neck cancer molecule; novel pipeline products comprising psoriasis molecules; and biosimilars products consisting of insulins, trastuzumab, pegfilgrastim, and bevacizumab. It also provides integrated discovery, development, and manufacturing services to pharmaceutical, biotechnology, animal healthcare, consumer good, and agrochemical companies. Biocon Limited was incorporated in 1978 and is headquartered in Bengaluru, India.
比較リストに追加
ウォッチリストに追加
ポートフォリオに追加
価格通知を追加

ISIN INE376G01013
Industry Biotechnology
Sector Health Care
Валюта inr
Валюта отчета inr
Див.доход ао 0.4195
Дивиденд ао 0.5
Сайт https://www.biocon.com
Цена ао 364.8
1日あたりの価格変動: +2.1% (364.8)
週ごとの価格変動: -2.59% (382.35)
月ごとの料金変更: +5.6% (352.7)
3ヶ月間の価格変動: +5.69% (352.4)
半年間の価格変動: +5.38% (353.45)
年間の価格変動: +32.57% (280.95)
3年間の価格推移: +3.47% (359.95)
5年間の価格推移: +30.25% (285.95)
10年間の価格推移: 0% (372.45)
年初からの価格変動: +6.31% (350.35)
すべてのパラメータ

過小評価

名前 意味 学年
P/S 2.13 7
P/BV 1.19 9
P/E 29.51 6
EV/EBITDA 16.97 6
合計: 7

効率

名前 意味 学年
ROA, % 1.89 1
ROE, % 5.43 2
合計: 2.17

配当金

名前 意味 学年
Div yield, % 0.4195 1.05
DSI 0.9286 9.29
合計: 2.2

義務

名前 意味 学年
Debt/EBITDA 6.48 0
合計: 3.4

成長の衝動

名前 意味 学年
収益性 Revenue, % 125.31 10
収益性 Ebitda, % 40.16 6
収益性 EPS, % 37.03 5
合計: 5.2
さらに詳しく

ETF 共有, % 年間の利益率, % 配当金, %
iShares MSCI India Small-Cap ETF 0.44091 0.4625 0.96163
iShares MSCI Emerging Markets Small-Cap ETF 0.13861 7.67 2.7853
Franklin FTSE India ETF 0.11361 20.52 1.25133
WisdomTree India Earnings Fund 0.03674 5.23 1.65591
JPMorgan ActiveBuilders Emerging Markets Equity ETF 0.03636 9.27 3.1658
SPDR Portfolio Emerging Markets ETF 0.02908 11.59 3.1879
Avantis Responsible Emerging Markets Equity ETF 0.0279 17.6 3.1719
Franklin FTSE Asia ex Japan ETF 0.02659 14.43 2.66768
Dimensional Emerging Markets Value ETF 0.01912 17.07 4.19508
John Hancock Multifactor Emerging Markets ETF 0.01141 4.68 3.42078
FlexShares Morningstar Emerging Markets Factor Tilt Index Fund 0.01046 12.46 3.59676
PIMCO RAFI Dynamic Multi-Factor Emerging Markets Equity ETF 0.01012 2.43 4.35382
Vanguard ESG International Stock ETF 0.01 6.39 3.07501
iShares Core MSCI Total International Stock ETF 0.00917 6.4 3.25258
Avantis Emerging Markets Equity ETF 0.00884 8.77 3.60513
Dimensional Emerging Markets Core Equity 2 ETF 0.00859 15.96 3.34087
Dimensional World ex U.S. Core Equity 2 ETF 0.00222 13.06 3.62488

スーパーバイザー 役職 支払い 生年
Mr. Siddharth Mittal BCom, CA, CPA MD, CEO & Director 47.88M 1978 (47 年)
Mr. Saurabh Paliwal Head of Investor Relations N/A
Mr. Mayank Verma Company Secretary & Compliance Officer 5.75M
Ms. Seema Shah Ahuja BA, MBA Global Head of Communications & Corporate Brand N/A 1966 (59 年)
Mr. Peter James Jonathan Bains Group Chief Executive Officer 3.28M 1957 (68 年)
Mr. Arun Gupta Head of Operations N/A
Mr. Atanu Roy Group Chief Information Officer N/A
Ms. Maninder Kapoor Puri Head of Human Resources N/A 1973 (52 年)
Dr. Kiran Mazumdar-Shaw B.Sc (Hons), B.Sc. Founder & Executive Chairperson 1953 (72 年)
Mr. Mukesh Kamath Chief Financial Officer

住所: India, Bengaluru, 20th KM Hosur Road - Googleマップで開く, Yandexマップを開く
Webサイト: https://www.biocon.com